Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage-Reference-Cited by-同舟云学术

Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage

Published:2021-01-06 Issue:1 Volume:35 Page:255-261
ISSN:1541-6933
Container-title:Neurocritical Care
language:en
Short-container-title:Neurocrit Care

Author:

Ammar Abdalla A.^ORCID,Ammar Mahmoud A.^ORCID,Owusu Kent A.,Brown Stacy C.,Kaddouh Firas,Elsamadicy Aladine A.,Acosta Julián N.,Falcone Guido J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s12028-020-01161-5.pdf

Reference20 articles.

1. Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) [package insert]. South San Francisco, CA: Portola Pharmaceuticals, Inc.; 2017.

2. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: Chest guideline and expert panel report. Chest. 2018;154:1121–201.

3. Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2:3257–91.

4. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76:594–622.

5. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Andexanet Alfa–Induced Heparin Resistance: Sustained Anticoagulant Inefficacy Despite Antithrombin Therapy;Journal of Cardiothoracic and Vascular Anesthesia;2024-08

2. Advances and Future Trends in the Diagnosis and Management of Intracerebral Hemorrhage;Neurologic Clinics;2024-08

3. Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor–associated major bleeds;Thrombosis Research;2024-08

4. Reprint of: Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal;Journal of the American Pharmacists Association;2024-08

5. Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation;Expert Review of Neurotherapeutics;2024-07-22